Everything tagged "healthcare" across the TickerSpark archives.
UnitedHealth Group Incorporated (UNH) gains 5.0% after reporting earnings beats, lifting shares as investors react positively to the stronger-than-expected results.
Elevance didn't get punished for missing the quarter; it got punished because the market no longer trusts the quality of the beat. Raised guidance matters less when Medicaid costs are still rising, membership is slipping, and management is calling 2026 the low point for profitability.
Elevance Health is working through a Medicaid-driven margin reset, but Q2 results, raised guidance, and Carelon growth point to a resilient earnings recovery. The stock looks attractively valued for a large managed-care platform with scale, cash flow, and multiple growth levers.
HCA Healthcare delivered strong revenue, earnings, and cash flow growth despite a choppy quarter. The stock looks attractively valued, but its heavy debt load keeps the risk profile elevated.
Abbott is evolving from a defensive healthcare name into a stronger medtech-led compounder, helped by Medical Devices growth and the Exact Sciences deal. Nutrition remains a drag, but the stock looks attractive on weakness rather than at any price.
Biogen’s business has stabilized, with growth products and LEQEMBI helping offset legacy MS pressure. The stock still looks reasonably priced for a selective Buy as cash flow and mix improve.
Elevance Health beat EPS and revenue, but the stock drops as investors focus on Medicaid margin pressure, membership declines, and the quality of the upside. This deep-dive breaks down the quarter’s mix, guidance, Carelon integration, and why a clean beat still failed to win the market.
Elevance Health Inc. (ELV) falls 10.0% even after earnings beats, as investors react to the latest results and outlook.
HCA’s latest guidance cut turned a policy risk into an earnings problem. When exchange coverage losses are already stripping roughly $400 million from one quarter, the scale-and-efficiency defense stops carrying the stock.
Alnylam just got the kind of competitive win biotech investors rarely get handed this cleanly: a rival late-stage ATTR-CM miss after AMVUTTRA already secured the label and commercial traction. With revenue up 65.2% year over year and AMVUTTRA driving more than $1 billion in quarterly product revenue, the stock still looks like the clearest winner in a narrowing field.
Ionis is evolving into a multi-product commercial RNA medicines company, with TRYNGOLZA and DAWNZERA driving real revenue growth and a larger market opportunity now open for TRYNGOLZA.
BridgeBio has evolved from a pipeline biotech into a commercial-stage rare-disease story, led by explosive Attruby sales and a late-stage pipeline. The stock still carries meaningful balance-sheet risk, but the launch momentum is real.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime